NCT04188119 2025-12-08
IMpALA
The Christie NHS Foundation Trust
Phase 2 Withdrawn
Clinical Trials
11 trialsNCT06557278 2025-10-21
COMUNITY
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT03554109 2025-02-21
TNBC
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT03563144 2025-02-21
QUILT-3.088: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT03574649 2025-02-21
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT06424717 2024-09-27
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
EMD Serono
Phase 2 Withdrawn
NCT05574504 2024-08-01
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
AdventHealth
Phase 2 Withdrawn
NCT05107427 2023-04-18
AVENU
4D pharma plc
Phase 2 Withdrawn
NCT03035630 2022-02-15
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT04874831 2021-11-18
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
4SC AG
Phase 2 Withdrawn
NCT03794596 2019-07-22
IMpALA
The Christie NHS Foundation Trust
Phase 2 Withdrawn